What is the difference between Diltiazem (generic) and Cardizem (Diltiazem), in terms of efficacy and usage for conditions like hypertension and angina?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diltiazem vs Cardizem: No Clinical Difference

Diltiazem and Cardizem are the same medication—Cardizem is simply the brand name for diltiazem. There is no difference in efficacy, mechanism of action, or clinical usage between generic diltiazem and brand-name Cardizem for treating hypertension and angina 1.

Mechanism and Clinical Effects

Both formulations work identically as calcium channel blockers (benzothiazepine class) by:

  • Inhibiting calcium influx during membrane depolarization in cardiac and vascular smooth muscle 1
  • Dilating coronary arteries (both epicardial and subendocardial), which relieves coronary artery spasm and increases oxygen supply 1
  • Reducing myocardial oxygen demand through decreases in heart rate and systemic blood pressure 1
  • Slowing AV nodal conduction and decreasing sinus node discharge rate, making it useful for rate control 2

Approved Indications

Both generic diltiazem and Cardizem are FDA-approved for:

  • Chronic stable angina 1
  • Angina due to coronary artery spasm (vasospastic angina) 1
  • Hypertension (though this requires higher doses than angina treatment) 3

Clinical Usage Guidelines

For Hypertension and Stable Angina

The American Heart Association and American College of Cardiology recommend diltiazem as:

  • First-line alternative when β-blockers are contraindicated or produce intolerable side effects in patients with hypertension and chronic stable angina 2
  • Preferred over dihydropyridine calcium channel blockers (like nifedipine) when rate control is needed 2
  • Symptom relief agent for patients already receiving nitrates and β-blockers 2

For Acute Coronary Syndromes

In NSTE-ACS (unstable angina/NSTEMI):

  • Diltiazem shows trends toward benefit when administered early to patients without heart failure 2
  • Can be used safely for symptom control in the absence of clinically significant LV dysfunction 2
  • The DATA trial demonstrated that intravenous diltiazem decreased death, MI, and recurrent ischemia at 35 days and 6 months 2

Critical Dosing Considerations

Common Dosing Error

Diltiazem is frequently underdosed in clinical practice:

  • For hypertension: The effective dose is commonly 360 mg/day, yet 70% of prescriptions are for 180-240 mg/day 3
  • For angina: The typical effective dose is 240 mg/day 3
  • FDA data shows a clear linear dose-response relationship through 480-540 mg/day for blood pressure lowering 3
  • The 90-120 mg/day range is essentially a "no-effect dose" 3

Formulation-Specific Dosing

  • Immediate-release: 30-90 mg four times daily 2
  • Sustained-release: 120-360 mg once daily 2
  • Maximum recommended dose: Up to 480 mg/day 4

Absolute Contraindications

Do not use diltiazem (generic or Cardizem) in patients with:

  • Left ventricular systolic dysfunction or heart failure 2, 4
  • Significant sinus or AV node dysfunction 2, 4
  • Hypotension 4
  • Advanced cardiac block without a pacemaker 4

Critical Drug Interaction Warning

Exercise extreme caution when combining diltiazem with β-blockers:

  • This combination increases risk of significant bradyarrhythmias and heart failure 2, 4
  • The synergistic effect can depress LV function and sinus/AV node conduction 2
  • When both are needed, close monitoring is mandatory 2

Comparative Efficacy Data

Diltiazem demonstrates equivalent outcomes to other major antihypertensive classes:

  • The INVEST trial showed no difference between verapamil (similar non-dihydropyridine CCB) and atenolol in cardiovascular death, MI, or revascularization in 22,000 hypertensive patients with chronic CAD 2
  • The NORDIL study found similar overall cardiovascular event rates for diltiazem versus diuretic/β-blocker combination 2
  • Diltiazem shows similar efficacy to β-blockers in relieving anginal symptoms 2

Pharmacokinetic Profile

Both formulations share identical pharmacokinetics:

  • Bioavailability: ~40% due to extensive first-pass metabolism 1
  • Protein binding: 70-80% 1
  • Half-life: 3.0-4.5 hours 1
  • Metabolism: Extensive hepatic; only 2-4% excreted unchanged in urine 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Anomalies in the dosing of diltiazem.

Clinical cardiology, 2000

Guideline

Verapamil Use in Hypertension

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.